Abstract
Skin necrosis is a recognized potential consequence of an inadvertent extravasation ofVinca alkaloids in the surrounding tissues during i.v. administration. Experimental studies suggest that hyaluronidase, an enzyme that degrades hyaluronic acid and improves the absorption of locally injected drugs, can reduce the risk of progressing to skin necrosis. On this basis, we used this enzyme as a local treatment after extravasations ofVinca alkaloids in seven patients. No patient suffered from subsequent skin necrosis. To the best of our knowledge, this is the first clinical report confirming the positive findings of experimental studies on the effectiveness of this antidote.
This is a preview of subscription content, log in via an institution to check access.
References
Britton RC, Habif DV (1953). Clinical uses of hyaluronidase: a current review. Surgery 33:917–942
Depierre A, Lemarie E, Dabouis G, Samak R, Krikorian A, Besenval M (1988) Phase II study of navelbine (NVB) in non small cell lung cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol 7:778
Dorr RT (1990) Antidotes to vescicant chemotherapy extravasations. Blood Rev 4:41–60
Dorr RT, Alberts DS (1985)Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. J Natl Cancer Inst 74:113–120
Schneider SM, Distelhorst CW (1989) Chemotherapy-induced emergencies. Semin Oncol 16:572–578
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bertelli, G., Dini, D., Forno, G.B. et al. Hyaluronidase as an antidote to extravasation ofVinca alkaloids: Clinical results. J Cancer Res Clin Oncol 120, 505–506 (1994). https://doi.org/10.1007/BF01191807
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01191807